• SOR102 combines anti-TNF and anti-IL-23 Vorabodies into a single dual acting molecule
• A trypsin cleavable linker releases the monomers to independently engage their targets throughout intestinal tissue
• SOR102 provides combination therapy locally within inflamed tissue with minimal risk of systemic immunosuppression

Overall benefits of dual targeting approach:

• Increased efficacy through blockade of different inflammatory mechanisms of IBD
• No systemic immunosuppression or safety issues with oral dosing, facilitating long-term treatment and full neutralisation of both targets
• A single product for manufacture, formulation and development